Cristina Guarnera Selected Research

Relapsing-Remitting Multiple Sclerosis

1/2017	Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.
1/2017	Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cristina Guarnera Research Topics

Disease

2	Infections 01/2017 - 01/2017
2	Relapsing-Remitting Multiple Sclerosis 01/2017 - 01/2017
1	Flushing 01/2017
1	Neoplasms (Cancer) 01/2017

Drug/Important Bio-Agent (IBA)

1	Dimethyl FumarateIBA 01/2017
1	CD52 AntigenIBA 01/2017
1	Alemtuzumab (Campath)FDA Link 01/2017
1	Monoclonal AntibodiesIBA 01/2017
1	teriflunomideIBA 01/2017
1	EnzymesIBA 01/2017
1	Fingolimod Hydrochloride (FTY720)FDA Link 01/2017

Therapy/Procedure

1	Therapeutics 01/2017